Record #203233 - GSI Repository

NEW DEAL

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Coordinator	SPARKS & CO ; ALAN BOYD CONSULTANTS LIMITED ; SEPS PHARMA ; LABORATOIRES MAYOLY SPINDLER ; SCIENSEED SL ; Consorci Institut D'Investigacions Biomediques August Pi I Sunyer ; Helmholtz-Zentrum für Infektionsforschung GmbH ; Inserm ; Atomic Energy and Alternative Energies Commission ; EUROPEAN RESEARCH SERVICES GMBH ; ProDigest (Belgium) ; NANOIMMUNOTECH SL
Grant period	2017-01-01 - 2021-09-30
Funding body	European Union
Call number	H2020-NMBP-2016-two-stage
Grant number	720905
Identifier	G:(EU-Grant)720905

Note: Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.

Recent Publications

There are no publications

Record created 2017-06-14, last modified 2023-02-12

Similar records

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

GSI Homepage \| GSI Library \| English Deutsch \| guest :: login GSI Repository
Search	Submit	Personalize Your alerts Your baskets Your searches	Help